Hemab Therapeutics Holdings, Inc. (COAG)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS4234941031
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Hemab Therapeutics Holdings, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:32. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Mar 2027 08:00 | -0.59 | — | — | Upcoming |
| 10 Nov 2026 07:00 | -0.55 | -0.58 | -5.6% | Miss |
| 14 Aug 2026 08:00 | -0.82 | — | — | — |
| 11 Aug 2026 07:00 | -0.82 | -0.80 | +2.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -63.9M | — | -2.33 | -31.3% | -61.5M |
| 2024 | 0 | — | -48.7M | — | -1.77 | — | -45.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 49.92 | 50.22 | 35.00 | 39.24 | -19.95% | 3,011,879 | |
| 02 Nov 2026 – 06 Nov 2026 | 41.67 | 49.12 | 39.96 | 49.02 | +18.26% | 2,193,800 | |
| 26 Oct 2026 – 30 Oct 2026 | 34.73 | 42.85 | 34.39 | 41.45 | +20.49% | 3,024,600 | |
| 19 Oct 2026 – 23 Oct 2026 | 30.12 | 36.70 | 29.88 | 34.40 | +14.40% | 1,680,800 | |
| 12 Oct 2026 – 16 Oct 2026 | 31.68 | 33.50 | 29.01 | 30.07 | -4.90% | 1,732,000 | |
| 05 Oct 2026 – 09 Oct 2026 | 31.11 | 33.93 | 27.38 | 31.62 | +1.64% | 2,344,000 | |
| 28 Sep 2026 – 02 Oct 2026 | 34.39 | 34.41 | 29.63 | 31.11 | -10.45% | 2,457,600 | |
| 21 Sep 2026 – 25 Sep 2026 | 41.20 | 43.21 | 34.01 | 34.74 | -15.66% | 2,191,800 | |
| 14 Sep 2026 – 18 Sep 2026 | 39.40 | 43.98 | 38.79 | 41.19 | +4.54% | 5,892,100 | |
| 08 Sep 2026 – 11 Sep 2026 | 44.03 | 46.20 | 38.98 | 39.40 | -11.28% | 1,629,000 | |
| 19 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ... (opens in a new tab) GuruFocus.com · 11 Nov 2026 23:03
- Hemab Therapeutics to Participate in Upcoming Investor Conferences (opens in a new tab) 11 Nov 2026 12:00
- Hemab (COAG) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 10 Nov 2026 19:31
- What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 10 Nov 2026 15:15
- Hemab Therapeutics Holdings (NASDAQ:COAG) Posts Wider Q3 Loss as Pipeline Catalysts Lift Stock (opens in a new tab) ChartMill · 10 Nov 2026 13:41
- Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 13:31
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (opens in a new tab) 10 Nov 2026 12:00
- Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 10 Nov 2026 10:03
- Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate (opens in a new tab) Benzinga · 10 Nov 2026 08:06
- Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia (opens in a new tab) 09 Nov 2026 12:00
- LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 (opens in a new tab) Benzinga · 09 Nov 2026 09:17
- Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia (opens in a new tab) Benzinga · 09 Nov 2026 08:08
- Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? (opens in a new tab) Simply Wall St. · 29 Sep 2026 02:07
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 39.38 USD
- Market cap
- 1.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -15.05× | Weak | 14.16× |
| Price / book | 4.29× | Weak | 3.5× |
| EV / EBITDA | -14.14× | Weak | 11.19× |
| Free cash flow yield | -3.3% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0× | Good | 0.4× |
| Current ratio | 33.86× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow COAG and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.